We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris (VTRS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Wall Street analysts forecast that Viatris (VTRS - Free Report) will report quarterly earnings of $0.64 per share in its upcoming release, pointing to a year-over-year decline of 4.5%. It is anticipated that revenues will amount to $3.78 billion, exhibiting an increase of 0.5% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Viatris metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Net Sales- Developed Markets' will reach $2.23 billion. The estimate indicates a change of -1.2% from the prior-year quarter.
Analysts forecast 'Net Sales- Greater China' to reach $675.37 million. The estimate indicates a change of +9.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- JANZ' will likely reach $291.56 million. The estimate suggests a change of -4.8% year over year.
Based on the collective assessment of analysts, 'Net Sales- Emerging Markets' should arrive at $565.37 million. The estimate points to a change of -0.9% from the year-ago quarter.
It is projected by analysts that the 'Net Sales- Developed Markets- Brands' will reach $1.24 billion. The estimate indicates a change of -0.5% from the prior-year quarter.
The consensus estimate for 'Net Sales- Developed Markets- Generics' stands at $992.94 million. The estimate indicates a year-over-year change of -2.1%.
According to the collective judgment of analysts, 'Revenues- Other revenues' should come in at $10.27 million. The estimate indicates a year-over-year change of -17.2%.
The collective assessment of analysts points to an estimated 'Net Sales- JANZ- Generics' of $147.72 million. The estimate indicates a change of +0.4% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- Emerging Markets- Brands' reaching $452.44 million. The estimate suggests a change of +6.7% year over year.
The average prediction of analysts places 'Net Sales- Emerging Markets- Generics' at $112.93 million. The estimate indicates a change of -22.8% from the prior-year quarter.
Analysts expect 'Net Sales- JANZ- Brands' to come in at $143.85 million. The estimate indicates a change of -9.6% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Total Net Sales' will reach $3.76 billion. The estimate suggests a change of +0.4% year over year.
Over the past month, Viatris shares have recorded returns of +7.9% versus the Zacks S&P 500 composite's -2% change. Based on its Zacks Rank #3 (Hold), VTRS will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Viatris (VTRS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Wall Street analysts forecast that Viatris (VTRS - Free Report) will report quarterly earnings of $0.64 per share in its upcoming release, pointing to a year-over-year decline of 4.5%. It is anticipated that revenues will amount to $3.78 billion, exhibiting an increase of 0.5% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Viatris metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Net Sales- Developed Markets' will reach $2.23 billion. The estimate indicates a change of -1.2% from the prior-year quarter.
Analysts forecast 'Net Sales- Greater China' to reach $675.37 million. The estimate indicates a change of +9.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- JANZ' will likely reach $291.56 million. The estimate suggests a change of -4.8% year over year.
Based on the collective assessment of analysts, 'Net Sales- Emerging Markets' should arrive at $565.37 million. The estimate points to a change of -0.9% from the year-ago quarter.
It is projected by analysts that the 'Net Sales- Developed Markets- Brands' will reach $1.24 billion. The estimate indicates a change of -0.5% from the prior-year quarter.
The consensus estimate for 'Net Sales- Developed Markets- Generics' stands at $992.94 million. The estimate indicates a year-over-year change of -2.1%.
According to the collective judgment of analysts, 'Revenues- Other revenues' should come in at $10.27 million. The estimate indicates a year-over-year change of -17.2%.
The collective assessment of analysts points to an estimated 'Net Sales- JANZ- Generics' of $147.72 million. The estimate indicates a change of +0.4% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- Emerging Markets- Brands' reaching $452.44 million. The estimate suggests a change of +6.7% year over year.
The average prediction of analysts places 'Net Sales- Emerging Markets- Generics' at $112.93 million. The estimate indicates a change of -22.8% from the prior-year quarter.
Analysts expect 'Net Sales- JANZ- Brands' to come in at $143.85 million. The estimate indicates a change of -9.6% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Total Net Sales' will reach $3.76 billion. The estimate suggests a change of +0.4% year over year.
View all Key Company Metrics for Viatris here>>>Over the past month, Viatris shares have recorded returns of +7.9% versus the Zacks S&P 500 composite's -2% change. Based on its Zacks Rank #3 (Hold), VTRS will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .